References
- Aronson JK. Rare diseases and orphan drugs. Br J Clin Pharmacol. 2006;61:243–245.
- Herder M. What is the purpose of the orphan drug act? PLoS Med. 2017;14:e1002191.
- Health promotion and disease prevention amendments of 1984, Pub. L. 98–551, 98 Stat 2815 (1984), § 4.
- EURORDIS (European Organization for Rare Diseases). Rare diseases: understanding this public health priority. 2005
- Bax BE. Biomarkers in rare diseases. Int J Mol Sci. 2021;22:673.
- Gülbakan B, Özgül RK, Yüzbaşioglu A, et al. Discovery of biomarkers in rare diseases: innovative approaches by predictive and personalized medicine. Epma J. 2016;7:24.
- Ayoglu B, Chaouch A, Lochmüller H, et al. Affinity proteomics within rare diseases: a BIO ‐ NMD study for blood biomarkers of muscular dystrophies. EMBO Mol Med. 2014;6:918–936.
- Nguengang Wakap S, Lambert DM, Olry A, et al. Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database. Eur J Hum Genet. 2020;28:165–173.
- European Commission - Rare Diseases. [cited 2021 Jan 26]. Available from: https://ec.europa.eu/health/non_communicable_diseases/rare_diseases_en
- About Rare Diseases | www.eurordis.org. [cited 2021 Jan 26]. Available from: https://www.eurordis.org/about-rare-diseases
- Lee CE, Singleton KS, Wallin M, et al. Rare genetic diseases: nature’s experiments on human development. iScience. 2020;23:101123.
- Stoller JK. The challenge of rare diseases. Chest. 2018;153:1309–1314.
- Orphanet: About rare diseases. [cited 2021 Jan 25]. Available from: https://www.orpha.net/consor/cgi-bin/Education_AboutRareDiseases.php?lng=EN
- Lopes MT, Koch VH, Sarrubbi-Junior V, et al. Difficulties in the diagnosis and treatment of rare diseases according to the perceptions of patients, relatives and health care professionals. Clinics. 2018;73:e68.
- Domaradzki J, Walkowiak D. Medical students’ knowledge and opinions about rare diseases: a case study from Poland. Intractable Rare Dis Res. 2019;8:252–259.
- Muscle GeneTable. [cited 2021 Jan 26]. Available from: http://www.musclegenetable.fr/
- Scotton C, Passarelli C, Neri M, et al. Biomarkers in rare neuromuscular diseases. Exp Cell Res. 2014;325:44–49.
- Al-Khalili Szigyarto C, Spitali P. Biomarkers of Duchenne muscular dystrophy: current findings. Degener Neurol Neuromuscul Dis. 2018;8:1–13.
- Crowther LM, Poms M, Plecko B. Multiomics tools for the diagnosis and treatment of rare neurological disease. J Inherit Metab Dis. 2018;41:425–434.
- Faundez V, Wynne M, Crocker A, et al. Molecular systems biology of neurodevelopmental disorders, rett syndrome as an archetype. Front Integr Neurosci. 2019;13:1–15.
- Gagne JJ, Thompson L, O’Keefe K, et al. Innovative research methods for studying treatments for rare diseases: methodological review. BMJ. 2014;349:g6802.
- Costanzo M, Zacchia M, Bruno G, et al. Integration of proteomics and metabolomics in exploring genetic and rare metabolic diseases. Kidney Dis. 2017;3:66–77.
- Fung ET, Wright J, Dalmasso EA. Proteomic strategies for biomarker identification: progress and challenges. Curr Opin Mol Ther. 2000;2:643–650.
- Johnston-Wilson NL, Bouton CMLS, Pevsner J, et al. Emerging technologies for large-scale screening of human tissues and fluids in the study of severe psychiatric disease. Int J Neuropsychopharmacol. 2001;4:83–92.
- Moler EJ, Chow ML, Mian IS. Analysis of molecular profile data using generative and discriminative methods. Physiol Genomics. 2001;2001:109–126.
- Lee PY, Saraygord-Afshari N, Low TY. The evolution of two-dimensional gel electrophoresis - from proteomics to emerging alternative applications. J Chromatogr A. 2020;1615:460763.
- Pino LK, Rose J, O’Broin A, et al. Emerging mass spectrometry-based proteomics methodologies for novel biomedical applications. Biochem Soc Trans. 2020;48:1953–1966.
- Tinti L, Spreafico A, Braconi D, et al. Evaluation of antioxiodant drugs for the treatment of ochronotic alkaptonuria in an in vitro human cell model. J Cell Physiol. 2010;225:84–91.
- Braconi D, Laschi M, Amato L, et al. Evaluation of anti-oxidant treatments in an in vitro model of alkaptonuric ochronosis. Rheumatology. 2010;49:1975–1983.
- Braconi D, Laschi M, Taylor AM, et al. Proteomic and redox-proteomic evaluation of homogentisic acid and ascorbic acid effects on human articular chondrocytes. J Cell Biochem. 2010;111:922–932.
- Braconi D, Bianchini C, Bernardini G, et al. Redox-proteomics of the effects of homogentisic acid in an in vitro human serum model of alkaptonuric ochronosis. J Inherit Metab Dis. 2011;34:1163–1176.
- Galderisi S, Cicaloni V, Milella MS, et al. Homogentisic acid induces cytoskeleton and extracellular matrix alteration in alkaptonuric cartilage. J Cell Physiol. 2021. in press. [cited 2021 Apr 20]. Available form: https://onlinelibrary.wiley.com/doi/full/10.1002/jcp.30284
- Braconi D, Millucci L, Spiga O, et al. Cell and tissue models of alkaptonuria. Drug Discov Today Dis Model. 2020;31:3–10.
- Braconi D, Bernardini G, Bianchini C, et al. Biochemical and proteomic characterization of alkaptonuric chondrocytes. J Cell Physiol. 2012;227:3333–3343.
- Braconi D, Bernardini G, Paffetti A, et al. Comparative proteomics in alkaptonuria provides insights into inflammation and oxidative stress. Int J Biochem Cell Biol. 2016;81:271–280.
- Lawrence RT, Perez EM, Hernández D, et al. The proteomic landscape of triple-negative breast cancer. Cell Rep. 2015;11:630–644.
- Lapek JD, Greninger P, Morris R, et al. Detection of dysregulated protein-association networks by high-throughput proteomics predicts cancer vulnerabilities. Nat Biotechnol. 2017;35:983–989.
- Frejno M, Chiozzi RZ, Wilhelm M, et al. Pharmacoproteomic characterisation of human colon and rectal cancer. Mol Syst Biol. 2017;13:951.
- Venable JD, Dong MQ, Wohlschlegel J, et al. Automated approach for quantitative analysis of complex peptide mixtures from tandem mass spectra. Nat Methods. 2004;1:39–45.
- Collins BC, Hunter CL, Liu Y, et al. Multi-laboratory assessment of reproducibility, qualitative and quantitative performance of SWATH-mass spectrometry. Nat Commun. 2017;8:1–12.
- Meier F, Brunner AD, Koch S, et al. Online parallel accumulation–serial fragmentation (PASEF) with a novel trapped ion mobility mass spectrometer. Mol Cell Proteomics. 2018;17:2534–2545.
- Meier F, Brunner AD, Frank M, et al. Parallel accumulation – serial fragmentation combined with data-independent acquisition (diaPASEF): bottom-up proteomics with near optimal ion usage. bioRxiv. bioRxiv. 2019;656207.
- Eldrid C, Thalassinos K. Developments in tandem ion mobility mass spectrometry. Biochem Soc Trans. 2020;48:2457–2466.
- Li J, Van Vranken JG, Pontano Vaites L, et al. TMTpro reagents: a set of isobaric labeling mass tags enables simultaneous proteome-wide measurements across 16 samples. Nat Methods. 2020;17:399–404.
- Cham JA, Bianco L, Barton C, et al. MRMaid-DB: a repository of published SRM transitions. J Proteome Res. 2010;9:620–625.
- Colangelo CM, Chung L, Bruce C, et al. Review of software tools for design and analysis of large scale MRM proteomic datasets. Methods. 2013;61:287–298.
- Stanfill BA, Nakayasu ES, Bramer LM, et al. Quality control analysis in real-time (QC-ART): a tool for real-time quality control assessment of mass spectrometry-based proteomics data. Mol Cell Proteomics. 2018;17:1824–1836.
- Yang H, Li YC, Zhao MZ, et al. Precision de novo peptide sequencing using mirror proteases of ac-lysarginase and trypsin for large-scale proteomics. Mol Cell Proteomics. 2019;18:773–785.
- Sharma V, Eckels J, Schilling B, et al. Panorama public: a public repository for quantitative data sets processed in skyline. Mol Cell Proteomics. 2018;17:1239–1244.
- Mullin AP, Gokhale A, Moreno-De-Luca A, et al. Neurodevelopmental disorders: mechanisms and boundary definitions from genomes, interactomes and proteomes. Transl Psychiatry. 2013;3:e329. Nature Publishing Group.
- Köhler S, Vasilevsky NA, Engelstad M, et al. The human phenotype ontology in 2017. Nucleic Acids Res. 2017;45:D865–D876.
- Cooper DN, Chen JM, Ball EV, et al. Genes, mutations, and human inherited disease at the dawn of the age of personalized genomics. Hum Mutat. 2010;31:631–655.
- Amberger JS, Bocchini CA, Schiettecatte F, et al. OMIM.org: online Mendelian Inheritance in Man (OMIM®), an online catalog of human genes and genetic disorders. Nucleic Acids Res. 2015;43:D789–D798.
- Boycott KM, Vanstone MR, Bulman DE, et al. Rare-disease genetics in the era of next-generation sequencing: discovery to translation. Nat Rev Genet. 2013;14:681–691.
- Tebani A, Afonso C, Marret S, et al. Omics-based strategies in precision medicine: toward a paradigm shift in inborn errors of metabolism investigations. Int J Mol Sci. 2016;17:1555.
- Karczewski KJ, Snyder MP. Integrative omics for health and disease. Nat Rev Genet. 2018;19:299–310.
- Nesvizhskii AI. Proteogenomics: concepts, applications and computational strategies. Nat Methods. 2014;11:1114–1125. Nature Publishing Group.
- Roos A, Thompson R, Horvath R, et al. Intersection of proteomics and genomics to “solve the unsolved” in rare disorders such as neurodegenerative and neuromuscular diseases. Proteomics - Clin Appl. 2018;12(2).
- Sheynkman GM, Shortreed MR, Cesnik AJ, et al. Proteogenomics: integrating next-generation sequencing and mass spectrometry to characterize human proteomic variation. Annu Rev Anal Chem. 2016;9:521–545.
- Hashimoto A, Takeuchi S, Kajita R, et al. Proteogenomic analysis of granulocyte macrophage colony-stimulating factor autoantibodies in the blood of a patient with autoimmune pulmonary alveolar proteinosis. Sci Rep. 2020;10:1–11.
- Trapnell BC, Whitsett JA, Nakata K. Pulmonary alveolar proteinosis. N Engl J Med. 2003;349:2527–2539.
- Haas D, Hoffmann GF. Mevalonate kinase deficiency and autoinflammatory disorders. N Engl J Med. 2007;356:2671–2673.
- Carapito R, Carapito C, Morlon A, et al. Basic and translational research multi-OMICS analyses unveil STAT1 as a potential modifier gene in mevalonate kinase deficiency. Ann Rheum Dis. 2018;77:1675–1687.
- Zlatic SA, Vrailas-Mortimer A, Gokhale A, et al. Rare disease mechanisms identified by genealogical proteomics of copper homeostasis mutant pedigrees. Cell Syst. 2018;6:368–380.e6.
- Tümer Z, Møller LB. Menkes disease. Eur J Hum Genet. 2010;18:511–518.
- Software List — ms-utils.org. [cited 2021 Apr 7]. Available from: https://ms-utils.org/
- RefSeq: NCBI Reference Sequence Database. [cited 2021 Apr 7]. Available from: https://www.ncbi.nlm.nih.gov/refseq/
- UniProt. [cited 2021 Apr 7]. Available from: https://www.uniprot.org/
- Cox J, Neuhauser N, Michalski A, et al. Andromeda: a peptide search engine integrated into the MaxQuant environment. J Proteome Res. 2011;10:1794–1805.
- MaxQuant Andromeda. [cited 2021 Apr 7]. Available from: http://coxdocs.org/doku.php?id=maxquant:andromeda:start
- Mascot search engine | Protein identification software for mass spec data. [cited 2021 Apr 7]. Available from: http://www.matrixscience.com/
- Xu T, Park SK, Venable JD, et al. ProLuCID: an improved SEQUEST-like algorithm with enhanced sensitivity and specificity. J Proteomics. 2015;129:16–24.
- Comet. [cited 2021 Apr 7]. Available from: http://comet-ms.sourceforge.net/
- X! Tandem. [cited 2021 Apr 7]. Available from: https://www.thegpm.org/tandem/
- Galaxy. [cited 2021 Apr 7]. Available from: https://usegalaxy.org/
- Integrated Proeomics Pipeline (IP2). [cited 2021 Apr 7]. Available from: http://www.integratedproteomics.com/products.html
- MaxQuant. [cited 2021 Apr 7]. Available from: https://www.maxquant.org/
- Röst HL, Sachsenberg T, Aiche S, et al. OpenMS: a flexible open-source software platform for mass spectrometry data analysis. Nat Methods. 2016;13:741–748.
- OpenMS – Open-source software for mass spectrometry analysis. [cited 2021 Apr 7]. Available from: https://www.openms.de/
- Carvalho PC, Fischer JSG, Chen EI, et al. PatternLab for proteomics: a tool for differential shotgun proteomics. BMC Bioinformatics. 2008;9:316.
- Carvalho PC, Fischer JSG, Xu T, et al. PatternLab: from mass spectra to label-free differential shotgun proteomics. Curr Protoc Bioinforma. 2012:Chapter 13:19.
- PatternLab for Proteomics. [cited 2021 Apr 7]. Available from: http://patternlabforproteomics.org/index.html
- Carvalho PC, Yates JR, Barbosa VC. Analyzing shotgun proteomic data with patternlab for proteomics. Curr Protoc Bioinforma. 2010;30. doi:10.1002/0471250953.bi1313s30.
- Carvalho PC, Lima DB, Leprevost FV, et al. Integrated analysis of shotgun proteomic data with PatternLab for proteomics 4.0. Nat Protoc. 2016;11:102–117.
- Progenesis QI for proteomics. [cited 2021 Apr 7]. Available from: http://www.nonlinear.com/progenesis/qi-for-proteomics/
- ProteinPilot Software. [cited 2021 Apr 7]. Available from: https://sciex.com/products/software/proteinpilot-software
- Thermo Fisher :: Orbitrap :: Proteome Discoverer. [cited 2021 Apr 7]. Available from: https://planetorbitrap.com/proteome-discoverer
- Skyline Targeted Mass Spec Environment. [cited 2021 Apr 7]. Available from: https://skyline.ms/project/home/software/Skyline/begin.view
- Taverna - Apache Incubator. [cited 2021 Apr 7]. Available from: https://incubator.apache.org/projects/taverna.html
- Trans-Proteomic Pipeline (TPP). [cited 2021 Apr 7]. Available from: http://tools.proteomecenter.org/wiki/index.php?title=Software:TPP
- iProX - integrated Proteome resources. [cited 2021 Apr 7]. Available from: https://www.iprox.org/
- jPOST | Japan Proteome Standard Repository/Database. [cited 2021 Apr 7]. Available from: https://jpostdb.org/
- MassIVE. [cited 2021 Apr 7]. Available from: https://massive.ucsd.edu/ProteoSAFe/static/massive.jsp
- OPD: Open Proteomics Database. [cited 2021 Apr 7]. Available from: http://data.marcottelab.org/MSdata/OPD/
- Panorama webserver. [cited 2021 Apr 7]. Available from: https://panoramaweb.org/project/PanoramaPublic/begin.view?
- PeptideAtlas. [cited 2021 Apr 7]. Available from: http://www.peptideatlas.org/
- Perez-Riverol Y, Csordas A, Bai J, et al. The PRIDE database and related tools and resources in 2019: improving support for quantification data. Nucleic Acids Res. 2019;47:D442–D450.
- PRIDE - Proteomics Identification Database. [cited 2021 Apr 7]. Available from: https://www.ebi.ac.uk/pride/
- GPMDB Proteome Database. [cited 2021 Apr 7]. Available from: http://gpmdb.thegpm.org/
- Babelomics 5. [cited 2021 Apr 7]. Available from: http://www.babelomics.org/
- Bioconductor. [cited 2021 Apr 7]. Available from: https://www.bioconductor.org/
- BioCyc Pathway/Genome Database Collection. [cited 2021 Apr 7]. Available from: https://biocyc.org/
- ClueGO. [cited 2021 Apr 7]. Available from: http://www.ici.upmc.fr/cluego/cluegoDownload.shtml
- Bindea G, Mlecnik B, Hackl H, et al. ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. Bioinformatics. 2009;25:1091–1093.
- Cytoscape: An Open Source Platform for Complex Network Analysis and Visualization. [cited 2021 Apr 7]. Available from: https://cytoscape.org/
- DAVID Functional Annotation Bioinformatics Microarray Analysis. [cited 2021 Apr 7]. Available from: https://david.ncifcrf.gov/.
- DisGeNET - a database of gene-disease associations. [cited 2021 Apr 7]. Available from: https://www.disgenet.org/
- Gene Ontology Resource. [cited 2021 Apr 7]. Available from: http://geneontology.org/
- IMPaLA: Integrated Molecular Pathway Level Analysis. [cited 2021 Apr 7]. Available from: http://impala.molgen.mpg.de/
- Ingenuity Pathway Analysis | QIAGEN Digital Insights. [cited 2021 Apr 7]. Available from: https://digitalinsights.qiagen.com/products-overview/discovery-insights-portfolio/analysis-and-visualization/qiagen-ipa/
- InterPro. [cited 2021 Apr 7]. Available from: http://www.ebi.ac.uk/interpro/
- Apweiler R, Attwood TK, Bairoch A, et al. The InterPro database, an integrated documentation resource for protein families, domains and functional sites. Nucleic Acids Res. 2001;29:37–40.
- Blum M, Chang HY, Chuguransky S, et al. The InterPro protein families and domains database: 20 years on. Nucleic Acids Res. 2021;49:D344–D354.
- Sandelin A, Alkema W, Engström P, et al. JASPAR: an open-access database for eukaryotic transcription factor binding profiles. Nucleic Acids Res. 2004;32:D91.
- JASPAR - a database of transcription factor binding profiles. [cited 2021 Apr 7]. Available from: http://jaspar.genereg.net/
- KEGG: Kyoto Encyclopedia of Genes and Genomes. [cited 2021 Apr 7]. Available from: https://www.genome.jp/kegg/
- mixOmics | | Omics Data Integration Project. [cited 2021 Apr 7]. Available from: http://mixomics.org/
- Rohart F, Gautier B, Singh A, et al. mixOmics: an R package for ‘omics feature selection and multiple data integration. PLoS Comput Biol. 2017;13:13.
- IntAct Molecular Interaction Database. [cited 2021 Apr 7]. Available from: https://www.ebi.ac.uk/intact/
- The Molecular INTeraction Database – An ELIXIR Core Resource. [cited 2021 Apr 7]. Available from: https://mint.bio.uniroma2.it/
- Licata L, Briganti L, Peluso D, et al. MINT, the molecular interaction database: 2012 Update. Nucleic Acids Res. 2012;40:40.
- OMIM - Online Mendelian Inheritance in Man. [cited 2021 Apr 7]. Available from: https://www.omim.org/
- PANDA-view. [cited 2021 Apr 7]. Available from: https://sourceforge.net/projects/panda-view/
- PathVisio biological pathway editor | pathvisio.github.io. [cited 2021 Apr 7]. Available from: https://pathvisio.github.io/
- Perseus. [cited 2021 Apr 7]. Available from: http://coxdocs.org/doku.php?id=perseus:start
- PANTHER - Gene List Analysis. [cited 2021 Apr 7]. Available from: http://www.pantherdb.org/
- Reactome Pathway Database. [cited 2021 Apr 7]. Available from: https://reactome.org/
- Supek F, Bošnjak M, Škunca N, et al. REVIGO summarizes and visualizes long lists of Gene Ontology terms. PLoS One. 2011;6:e21800. cited 2021 Apr 7. Available from: http://revigo.irb.hr/
- Rhea- Annotated reactions database. [cited 2021 Apr 7]. Available from: https://www.rhea-db.org/
- STRING: functional protein association networks. [cited 2021 Apr 7]. Available from: https://string-db.org/
- Martens M, Ammar A, Riutta A, et al. WikiPathways: connecting communities. Nucleic Acids Res. 2021;49:D613–D621.
- WikiPathways - WikiPathways. [cited 2021 Apr 7]. Available from: https://www.wikipathways.org/index.php/WikiPathways
- Urfer W, Grzegorczyk M, Jung K. Statistics for proteomics: a review of tools for analyzing experimental data. Proteomics. 2006;6:48–55.
- Gatto L, Christoforou A. Using R and bioconductor for proteomics data analysis. Biochim Biophys Acta - Proteins Proteomics. 2014;1844:42–51.
- Pathguide: the pathway resource list. [cited 2021 Apr 7]. Available from: http://pathguide.org/
- Wu X, Al HM, Chen JY. Pathway and network analysis in proteomics. J Theor Biol. 2014;362:44–52.
- Cicaloni V, Spiga O, Dimitri GMGM, et al. Interactive alkaptonuria database: investigating clinical data to improve patient care in a rare disease. Faseb J. 2019;33:12696–12703.
- Spiga O, Cicaloni V, Visibelli A, et al. Towards a precision medicine approach based on machine learning for tailoring medical treatment in alkaptonuria. Int J Mol Sci. 2021;22:1187.
- Bhowmick SS, Saha I, Bhattacharjee D, et al. Genome-wide analysis of NGS data to compile cancer-specific panels of miRNA biomarkers. PLoS One. 2018;13:e0200353.
- Braconi D, Santucci A. Models of rare diseases. Drug Discov Today Dis Model. 2020;31:1–2.
- Lochmüller H, Badowska DM, Thompson R, et al. RD-Connect, NeurOmics and EURenOmics: collaborative European initiative for rare diseases. Eur J Hum Genet. 2018;26:778–785.
- Burns J, Wilding CP, L Jones R, et al. Proteomic research in sarcomas – current status and future opportunities. Semin Cancer Biol. 2020;61:56–70.
- Bernardini G, Laschi M, Serchi T, et al. Proteomics and phosphoproteomics provide insights into the mechanism of action of a novel pyrazolo[3,4-d]pyrimidine Src inhibitor in human osteosarcoma. Mol Biosyst. 2014;10:1305–1312.
- Garrod AE. The lessons of rare maladies: annual oration before the Medical Society of London by Sir Archibald Garrod. Br Med J. 1928;1:914–915.
- Velez G, Mahajan VB. Molecular surgery: proteomics of a rare genetic disease gives insight into common causes of blindness. iScience. 2020;23:101667.
- Gambassi S, Geminiani M, Thorpe SD, et al. Smoothened-antagonists reverse homogentisic acid-induced alterations of Hedgehog signaling and primary cilium length in alkaptonuria. J Cell Physiol. 2017;232:3103–3111.
- Thorpe SD, Gambassi S, Thompson CL, et al. Reduced primary cilia length and altered Arl13b expression are associated with deregulated chondrocyte Hedgehog signaling in alkaptonuria. J Cell Physiol. 2017;232:2407–2417.
- Mitri E, Millucci L, Merolle L, et al. A new light on Alkaptonuria: a Fourier-transform infrared microscopy (FTIRM) and low energy X-ray fluorescence (LEXRF) microscopy correlative study on a rare disease. Biochim Biophys Acta Gen Subj. 2017;1861:1000–1008.
- Gallagher JA, Ranganath LR, Boyde A. Lessons from rare diseases of cartilage and bone. Curr Opin Pharmacol. 2015;22:107–114.
- Sidransky E, Lopez G. The link between the GBA gene and parkinsonism. Lancet Neurol. 2012;11:986–998.
- Redekop WK, Mladsi D. The faces of personalized medicine: a framework for understanding its meaning and scope. Value Heal. 2013;16:S4–S9.
- Schleidgen S, Klingler C, Bertram T, et al. What is personalized medicine: sharpening a vague term based on a systematic literature review. BMC Med Ethics. 2013;14:55.
- Di Paolo A, Sarkozy F, Ryll B, et al. Personalized medicine in Europe: not yet personal enough? BMC Health Serv Res. 2017;17:289.
- Perlman RL, Govindaraju DR, Archibald E. Garrod: the father of precision medicine. Genet Med. 2016;18:1088–1089.
- Garrod AE. The incidence of alkaptonuria: a study in chemical individuality. Lancet. 1902;160:1616–1620.
- Garrod AE. The inborn factors in disease: an essay. Oxford, UK: Oxford University Press; 1931.
- Garrod AE. Inborn errors of metabolism. London, UK: Henry Frowde and Hodder & Stoughton; 1909.
- Šimić G. Rare diseases and omics-driven personalized medicine. Croat Med J. 2019;60:485–492.
- Tabor HK, Goldenberg A. What precision medicine can learn from rare genetic disease research and translation. AMA J Ethics. 2018;20:E834–E840.
- Spiga O, Cicaloni V, Fiorini C, et al. Machine learning application for development of a data-driven predictive model able to investigate quality of life scores in a rare disease. Orphanet J Rare Dis. 2020;15:46.
- Spiga O, Cicaloni V, Zatkova A, et al. A new integrated and interactive tool applicable to inborn errors of metabolism: application to alkaptonuria. Comput Biol Med. 2018;103:1–7.
- Rossi A, Giacomini G, Cicaloni V, et al. AKUImg: a database of cartilage images of Alkaptonuria patients. Comput Biol Med. 2020;122:103863.
- Spiga O, Cicaloni V, Bernini A, et al. ApreciseKUre: an approach of precision medicine in a rare disease. BMC Med Inform Decis Mak. 2017;17:42.
- HUPO - Mission. [cited 2021 Apr 7]. Available from: https://www.hupo.org/mission
- Adhikari S, Nice EC, Deutsch EW, et al. A high-stringency blueprint of the human proteome. Nat Commun. 2020;11:5301.
- Bell PA, Solis N, Kizhakkedathu JN, et al. Proteomic and N-Terminomic TAILS analyses of human alveolar bone proteins: improved protein extraction methodology and lysarginase digestion strategies increase proteome coverage and missing protein identification. J Proteome Res. 2019;18:4167–4179.
- Sun A, Jiang Y, Wang X, et al. Liverbase: a comprehensive view of human liver biology. J Proteome Res. 2010;9:50–58.
- Ogino S, Nishihara R, Vanderweele TJ, et al. The role of molecular pathological epidemiology in the study of neoplastic and non-neoplastic diseases in the era of precision medicine HHS public access. Epidemiology. 2016;27:602–611.
- Ogino S, Nowak JA, Hamada T, et al. Insights into pathogenic interactions among environment, host, and tumor at the crossroads of molecular pathology and epidemiology. Annu Rev Pathol Mech Dis. 2019;14:83–103.
- Hamada T, Keum NN, Nishihara R, et al. Molecular pathological epidemiology: new developing frontiers of big data science to study etiologies and pathogenesis. J Gastroenterol. 2017;52:265–275.
- Ogino S, King EE, Beck AH, et al. Interdisciplinary education to integrate pathology and epidemiology: towards molecular and population-level health science. Am J Epidemiol. 2012;176:659–667.